OBGYN & Reproduction Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of OBGYN & Reproduction Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dry Eye Syndrome
Pharmaceutical company announces dry eye syndrome clinical trial fully enrolled
July 4th, 2005
Nascent Pharmaceuticals, Inc., announced that it has completed enrollment of a 90-patient phase IIb clinical trial of NP50301, Nascent's topical ophthalmic therapeutic eye drop for treating dry eye syndrome (DES) in postmenopausal women. The clinical trial is a randomized, vehicle controlled, double masked study, with 30 patients in each of three arms, receiving either placebo, or one of two active doses. Data is being collected for both subjective symptoms and objective signs throughout the 14-week trial period. "Completion of enrollment of the phase IIb clinical trial is a significant milestone in the development of NP50301," said Gene Barnett,...
Source: OBGYN & Reproduction Week (2005-07-04)
|
